AUSTIN, Texas, June 28, 2017 /PRNewswire/ -- Luminex
Corporation (NASDAQ: LMNX) today announced that it has received
CE-IVD marking for the ARIES® Norovirus Assay, an easy
to use, sample to answer test for rapid detection and
differentiation of norovirus genogroup I and II from stool
specimens of individuals with symptoms of acute
gastroenteritis.
The CDC reports that norovirus is estimated to be the most
common cause of acute gastroenteritis worldwide, and each year,
norovirus causes over 200,000 deaths and a global economic burden
of more than $60
billion.1
As the fifth CE-marked assay for use on Luminex's
ARIES® Systems, the Norovirus Assay adds to a growing
menu of tests for the ARIES® platform. The system is
designed to run in multiple laboratory shifts and allows labs to
simultaneously run both IVD and LDT assays in a sample to answer
format when using a Universal Assay Protocol.
"We are very excited to add the simple and cost-effective
Norovirus Assay to our expanding menu of assays for
ARIES®," said Thomas
Pracht, managing director of Luminex Europe. "The
ARIES® Norovirus Assay offers excellent performance for
high confidence in results and reduced hands-on time compared to
other molecular assays. Further, by enabling rapid and accurate
diagnosis even outside office hours, the assay can expedite
appropriate infection control measures."
ARIES® Systems automate all aspects of testing, from
sample preparation through analysis, providing answers in less than
2 hours with minimal hands-on time while enabling easy
implementation on weekends and night shifts. The ARIES®
Norovirus Assay, a real-time polymerase chain reaction (PCR)-based
qualitative in vitro diagnostic test, is part of Luminex's
comprehensive gastroenterological testing menu that also includes
the xTAG® Gastrointestinal Pathogen Panel
(GPP), VERIGENE® Enteric Pathogens Test (EP), and
the ARIES® C. difficile Assay (RUO).
The ARIES® Norovirus Assay is intended to aid in the
diagnosis of norovirus infections when used in conjunction with
clinical evaluation, laboratory findings, and epidemiological
information. The assay also aids in the detection and
identification of norovirus infections in the context of outbreaks.
For more information, please visit
www.luminexcorp.com/norovirus
About ARIES® Systems
ARIES® Systems are sample to answer molecular
diagnostic systems designed to increase laboratory efficiency,
ensure result accuracy, and fit seamlessly into today's lean
laboratory environment. ARIES® uses internal barcode
scanning and other advanced features to minimize operator errors.
Independent modules support from one to six cassettes, allowing for
both STAT and batch testing of IVD assays and laboratory developed
tests (LDTs) with MultiCode® Reagents when using a
universal assay protocol. An integrated touchscreen PC eliminates
the need for a separate computer, standalone keyboard, and mouse,
maximizing valuable bench space.
To learn more or request a demo, please visit:
http://www.luminexcorp.com/ARIES
About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable,
timely, and actionable answers, ultimately advancing health.
We offer a wide range of solutions applicable in diverse markets
including clinical diagnostics, pharmaceutical drug discovery,
biomedical research, genomic and proteomic research, biodefense
research, and food safety. We accelerate reliable answers while
simplifying complexity and deliver certainty with a seamless
experience. To learn more about Luminex, please visit us at
www.luminexcorp.com.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding the available market and customer acceptance for
ARIES®, future revenue growth anticipated for
ARIES®, and the development, testing and
regulatory approval progress of our pipeline products, including
ARIES® related assays. The words "believe",
"expect", "intend", "anticipates", "confident", "will", "could",
"should", and similar expressions are intended to further
identify such forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results or performance could
differ materially from those anticipated in such forward-looking
statements. Factors that could cause Luminex's actual results or
performance to differ materially include risks and uncertainties
relating to, among others, our ability to launch products on time,
the timing of regulatory approvals, the outcome of clinical trials
as well as the risks discussed under the heading "Risk Factors" in
Luminex's Reports on Forms 10-K and 10-Q, as filed with the
Securities and Exchange Commission. The forward looking statements
contained herein represent the judgment of Luminex as of the date
of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
References:
- Lopman BA, Steele D, Kirkwood CD, Parashar UD (2016) The Vast
and Varied Global Burden of Norovirus: Prospects for Prevention and
Control. PLoS Med 13(4): e1001999.
https://doi.org/10.1371/journal.pmed.1001999
Contacts:
Luminex Investor Contact
Harriss Currie,
512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com
Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing Communications
cvalle@luminexcorp.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-receives-ce-ivd-mark-for-aries-norovirus-assay-300480707.html
SOURCE Luminex Corporation